Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial

Pasi A. Jänne^*, Michel van den Heuvel, Fabrice Barlesi, Manuel Cobo, Julien Mazieres, Lucio Crinò, Sergey Orlov, Fiona Blackhall, Juergen Wolf, Pilar Garrido, Artem Poltoratskiy, Gabriella Mariani, Dana Ghiorghiu, Elaine Kilgour, Paul Smith, Alexander Kohlmann, David J. Carlile, David Lawrence, Karin Bowen, Johan Vansteenkiste

^*Corresponding author for this work

Division of Cancer Sciences (L5)
Cancer Research UK Manchester Institute

Dana-Farber Cancer Institute
Netherlands Cancer Institute
UMR 6242 CNRS
Carlos Haya University Hospital
Centre Hospitalier Universitaire de Toulouse
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
First Pavlov State Medical University of St Petersburg
University Hospital Cologne
Hospital Universitario Ramón y Cajal de Madrid
N.N. Petrov Institute of Oncology
Katholieke Universiteit Leuven
AstraZeneca

Research output: Contribution to journal › Article › peer-review

Sort by
Weight
Alphabetically

Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial

Fingerprint

Pharmacology, Toxicology and Pharmaceutical Science